ClinicalTrials.gg
CompletedNCT02696434Updated Feb 12, 2019Results posted

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

A Phase 3 interventional study of Naltrexone and Placebo in Opioid Use Disorder, sponsored by Alkermes, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-02-12.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing naltrexone in Opioid-Related Disorders — 1 open to participants now, 2 under way, none of them phase 3. Naltrexone · Opioid-Related Disorders.

Enrollment
22nd of 52
101 · median 61
Started
2016
with 2 others
Phase 3
11 of 52
none open now
Registered
37th of 52
by date
Lead sponsor
6 of 52
Alkermes, Inc.

Among the 52 studies testing naltrexone in Opioid-Related Disorders, this one is the 22nd largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 37th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

1 of the 52 studies testing naltrexone in Opioid-Related Disorders is open now. Recruiting first, the newest first:

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing naltrexone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of VIVITROL.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • naltrexone
  • VIVITROL
  • buprenorphine
  • opioid
  • addiction
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide
  • Willing and able to provide government-issued identification
  • Has a (BMI) of 18.0-40.0 kg/m\^2
  • Has a history of opioid use disorder diagnosis for at least 6 months
  • Has a history of prescribed buprenorphine (or buprenorphine/naloxone) maintenance for the prior 3 or more consecutive months and is currently buprenorphine-maintained
  • Must be voluntarily seeking treatment for opioid use disorder and be motivated to receive antagonist therapy
  • Willing to abide by the requirements for the duration of the study
  • Additional criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Is pregnant, planning to become pregnant or breastfeeding during the study
  • Has a positive urine drug screen for opiates or oxycodone at screening
  • Has used methadone within 30 days prior to study Day -5
  • Has used naltrexone (oral or VIVITROL) within the 90 days prior to Day -5
  • Has a history of seizures or has received anticonvulsant therapy within the past 5 years for treatment of seizures (use of anticonvulsant during the past detoxification is not exclusionary)
  • Has a condition, disease state, or previous medical history that would preclude safe participation in the study or affect the ability to adhere to the protocol visit schedule, requirements, or assessments
  • Has a current diagnosis of schizoaffective disorder, bipolar disorder, or untreated and unstable major depressive disorder
  • Is currently physiologically dependent on any psychoactive substance (except opioids, caffeine, or nicotine) requiring medical intervention for detoxification
  • Has a history of or adverse reaction to buprenorphine, naltrexone, VIVITROL, or naloxone
  • Additional criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Active comparator
    PBO NTX + BUP

    Placebo naltrexone + buprenorphine

    Drug: Placebo · Drug: Buprenorphine

  • Experimental
    NTX + BUP

    Naltrexone + buprenorphine

    Drug: Naltrexone · Drug: Buprenorphine

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8

    Demonstrated by mild opioid withdrawal symptoms (Clinical Opiate Withdrawal Scale \[COWS\] \</=12 or Subjective Opiate Withdrawal Scale \[SOWS\] \</=10) following VIVITROL administration. The COWS is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal). The SOWS is a 16-item self-report questionnaire designed to measure the severity of opioid withdrawal symptoms. The subject rates the intensity of symptoms using a 5-point scale. The range of SOWS scores is 1-10 (mild); 11-20 (moderate); and 21-30 (severe).

    Time frame: 8 days

Secondary outcomes

  1. Proportion of Days With COWS Peak Score </=12 During the Treatment Period Prior to the VIVITROL Injection

    The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

    Time frame: 1 week

  2. Proportion of Post-VIVITROL Days (Days 9-11) in Which Subjects in Each Group Demonstrate Mild Opioid Withdrawal

    COWS score \</=12; The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

    Time frame: Days 9-11

  3. Mean Peak COWS Scores During the Treatment Period (Days 1/1a-7)

    The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

    Time frame: Up to 7 days

  4. Area Under the Curve (AUC) for COWS Scores During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period

    The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal). The daily AUC COWS score is derived based on the actual time (unit in minutes) COWS administered on each day by using the linear trapezoidal rule, and then divided by the COWS administration duration (last COWS administration time minus first COWS administration time) for that day. The normalized AUC COWS score is the summation of daily AUC COWS score during the relevant period divided by the number of days with daily AUC COWS score.

    Time frame: The COWS was administered 4-6 times per day during the Treatment Period

  5. Mean Score for "Desire for Opioids" Visual Analog Scale (VAS) During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period

    The Desire for Opioids VAS uses a 100-mm, horizontal linear scale, with 0 anchored on the left representing "no desire for opioids" and 100 anchored on the right representing "strongest imaginable desire for opioids."

    Time frame: Up to 11 days

  6. Incidence of Adverse Events (AEs)

    Number and percentage of subjects who experienced AEs.

    Time frame: Up to 42 days

07

Results

Posted Feb 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneNTX + BUPPBO NTX + BUP
Started5051
Completed2833
Not completed2218
Withdrew: Adverse event31
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject1412
Withdrew: Physician decision01

Outcome measures

PrimaryProportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8

Demonstrated by mild opioid withdrawal symptoms (Clinical Opiate Withdrawal Scale \[COWS\] \</=12 or Subjective Opiate Withdrawal Scale \[SOWS\] \</=10) following VIVITROL administration. The COWS is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal). The SOWS is a 16-item self-report questionnaire designed to measure the severity of opioid withdrawal symptoms. The subject rates the intensity of symptoms using a 5-point scale. The range of SOWS scores is 1-10 (mild); 11-20 (moderate); and 21-30 (severe).

Time frame:
8 days
Reported as:
Count of participants · Participants
Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8
ParticipantsNTX + BUPPBO NTX + BUP
Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 83538
Statistical analysis
  • NTX + BUP vs PBO NTX + BUP · Regression, Logistic · p = 0.407 · Odds ratio (or): 0.68 · 95% CI 0.28 to 1.68
SecondaryProportion of Days With COWS Peak Score </=12 During the Treatment Period Prior to the VIVITROL Injection

The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

Time frame:
1 week
Reported as:
Mean · Days
Proportion of Days With COWS Peak Score </=12 During the Treatment Period Prior to the VIVITROL Injection
DaysNTX + BUPPBO NTX + BUP
Proportion of Days With COWS Peak Score </=12 During the Treatment Period Prior to the VIVITROL Injection5.8 ± 1.616.3 ± 1.36
SecondaryProportion of Post-VIVITROL Days (Days 9-11) in Which Subjects in Each Group Demonstrate Mild Opioid Withdrawal

COWS score \</=12; The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

Time frame:
Days 9-11
Reported as:
Mean · Days
Proportion of Post-VIVITROL Days (Days 9-11) in Which Subjects in Each Group Demonstrate Mild Opioid Withdrawal
DaysNTX + BUPPBO NTX + BUP
Proportion of Post-VIVITROL Days (Days 9-11) in Which Subjects in Each Group Demonstrate Mild Opioid Withdrawal2.4 ± 0.872.6 ± 0.81
SecondaryMean Peak COWS Scores During the Treatment Period (Days 1/1a-7)

The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal).

Time frame:
Up to 7 days
Reported as:
Mean · score on a scale
Mean Peak COWS Scores During the Treatment Period (Days 1/1a-7)
score on a scaleNTX + BUPPBO NTX + BUP
Mean Peak COWS Scores During the Treatment Period (Days 1/1a-7)6.0 ± 3.715.0 ± 2.78
SecondaryArea Under the Curve (AUC) for COWS Scores During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period

The Clinical Opiate Withdrawal Scale (COWS) is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal). The daily AUC COWS score is derived based on the actual time (unit in minutes) COWS administered on each day by using the linear trapezoidal rule, and then divided by the COWS administration duration (last COWS administration time minus first COWS administration time) for that day. The normalized AUC COWS score is the summation of daily AUC COWS score during the relevant period divided by the number of days with daily AUC COWS score.

Time frame:
The COWS was administered 4-6 times per day during the Treatment Period
Reported as:
Mean · score on a scale
Area Under the Curve (AUC) for COWS Scores During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period
score on a scaleNTX + BUPPBO NTX + BUP
Area Under the Curve (AUC) for COWS Scores During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period4.5 ± 3.113.9 ± 2.29
SecondaryMean Score for "Desire for Opioids" Visual Analog Scale (VAS) During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period

The Desire for Opioids VAS uses a 100-mm, horizontal linear scale, with 0 anchored on the left representing "no desire for opioids" and 100 anchored on the right representing "strongest imaginable desire for opioids."

Time frame:
Up to 11 days
Reported as:
Mean · score on a scale
Mean Score for "Desire for Opioids" Visual Analog Scale (VAS) During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period
score on a scaleNTX + BUPPBO NTX + BUP
Mean Score for "Desire for Opioids" Visual Analog Scale (VAS) During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period6.3 ± 12.628.3 ± 14.43
SecondaryIncidence of Adverse Events (AEs)

Number and percentage of subjects who experienced AEs.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs)
ParticipantsNTX + BUPPBO NTX + BUP
Incidence of Adverse Events (AEs)3837

Adverse events

Collected over Adverse event data were collected over a period of 42 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NTX + BUP0/50 (0%)0/50 (0%)36/50 (72%)
PBO NTX + BUP0/51 (0%)1/51 (2%)34/51 (66.7%)
Most frequent serious events
Most frequent serious events
EventNTX + BUPPBO NTX + BUP
Suicidal IdeationPsychiatric disorders0/501/51
Psychotic DisorderPsychiatric disorders0/501/51
Most frequent other events
Showing 10 of 17
Most frequent other events
EventNTX + BUPPBO NTX + BUP
DiarrhoeaGastrointestinal disorders16/509/51
AnxietyPsychiatric disorders15/5015/51
InsomniaPsychiatric disorders13/5013/51
MyalgiaMusculoskeletal and connective tissue disorders10/506/51
NauseaGastrointestinal disorders9/505/51
Abdominal Pain UpperGastrointestinal disorders7/506/51
ConstipationGastrointestinal disorders3/506/51
HeadacheNervous system disorders5/503/51
RestlessnessPsychiatric disorders4/505/51
Back PainMusculoskeletal and connective tissue disorders4/502/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)NTX + BUPPBO NTX + BUPTotal
Mean36.3 ± 9.4134.8 ± 7.5835.6 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)NTX + BUPPBO NTX + BUPTotal
Female141630
Male363571
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NTX + BUPPBO NTX + BUPTotal
Hispanic or Latino235
Not Hispanic or Latino484896
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NTX + BUPPBO NTX + BUPTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American437
White464793
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)NTX + BUPPBO NTX + BUPTotal
United States5051101
08

Study locations

9 sites
  • Segal Institute for Clinical Research
    Lauderhill, Florida 33308, United States
  • Research Centers of America, LLC
    Oakland Park, Florida 33334, United States
  • Neuroscience Research Institute, Inc.
    Winfield, Illinois 60190, United States
  • John Hopkins School of Medicine
    Baltimore, Maryland 21205-1911, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • New York State Psychiatric Institute
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • University of Pennsylvania Treatment Research Center
    Philadelphia, Pennsylvania 19104, United States
  • Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Publications

  • Mannelli P, Douaihy AB, Akerman SC, Legedza A, Fratantonio J, Zavod A, Sullivan MA. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. Am J Addict. 2022 Mar;31(2):142-147. doi: 10.1111/ajad.13264. Epub 2022 Feb 9. PubMed 35137481 ↗
  • Mannelli P, Douaihy AB, Zavod A, Legedza A, Akerman SC, Sullivan MA. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone. Am J Drug Alcohol Abuse. 2021 Nov 2;47(6):753-759. doi: 10.1080/00952990.2021.1969659. Epub 2021 Nov 9. PubMed 34752714 ↗
  • Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. PubMed 32777606 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2016
First posted
Mar 2, 2016
Start
Apr 2016
Primary completionActual
Nov 2017
CompletionActual
Nov 30, 2017
Results first posted
Feb 12, 2019
Last update
Feb 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02696434
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Apr 2016
Primary completion
Nov 2017
Completion
Nov 30, 2017
Results posted
Feb 12, 2019
Last update
Feb 12, 2019

Study contacts

Maria A. Sullivan, MD, PhD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion